Summarized by Masters of Longevity from Longevity Technology.
A short news article previewing a clinical update about a Parkinson’s study testing an oral resveratrol formulation and concurrent corporate strategy review.
Key Takeaways
- The RESET Phase 2a trial will primarily assess JOTROL’s safety, tolerability, and pharmacokinetics over a 12-week period in Parkinson’s patients.
- JOTROL is a patented micellar formulation of trans-resveratrol designed to increase absorption and cerebrospinal fluid exposure compared with conventional resveratrol.
- Jupiter Neurosciences is pursuing strategic options, including potential sale or licensing of assets, while continuing the clinical study.
